Related Experiment Video

Updated: Jun 20, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Early diagnosis of Alzheimer's disease: is MCI too late?

Ronald C Petersen1

  • 1Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. peter8@mayo.edu

Current Alzheimer Research
|August 20, 2009
PubMed

Insights

Mild cognitive impairment (MCI) bridges normal aging and Alzheimer's disease, offering an early detection window. Research is identifying MCI progression predictors to improve clinical trials and dementia diagnosis.

Area of Science:

  • Gerontology
  • Neurology
  • Cognitive Science

Background:

  • Aging and dementia research is progressing towards earlier symptom identification.
  • Mild cognitive impairment (MCI) serves as a crucial intermediate state between normal aging and early Alzheimer's disease.
  • Understanding MCI is vital for developing timely interventions and improving patient outcomes.

Purpose of the Study:

  • To review the expanding body of research on mild cognitive impairment (MCI).
  • To discuss the epidemiological characteristics and frequency of MCI in the general population.
  • To explore predictors of MCI progression to Alzheimer's disease and their implications for clinical trials.

Main Methods:

  • Epidemiological studies to characterize MCI frequency.
  • Analysis of predictors for MCI progression to Alzheimer's disease.
  • Review of neuropathological findings in MCI.

Main Results:

  • MCI represents an intermediate clinical stage between aging and Alzheimer's disease.
  • Epidemiologic studies are defining the prevalence of MCI.
  • Predictors for faster progression from MCI to Alzheimer's disease have been identified.

Conclusions:

  • MCI research is rapidly expanding, providing insights into early dementia detection.
  • Identifying MCI progression factors can refine clinical trial designs.
  • Neuropathology of MCI is distinct and intermediate between normal aging and Alzheimer's disease.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.